Format

Send to

Choose Destination
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):440-446. doi: 10.1182/asheducation-2017.1.440.

Evolving treatment paradigms in sickle cell disease.

Author information

1
Department of Pediatrics, University of Illinois at Chicago, Chicago, IL; and.
2
Jesse Brown Veterans Affairs Medical Center, Chicago, IL.

Abstract

Sickle cell disease (SCD) is an inheritable hemoglobinopathy characterized by polymerization of hemoglobin S in red blood cells resulting in chronic hemolytic anemia, vaso-occlusive painful crisis, and multiorgan damage. In SCD, an increased reactive oxygen species (ROS) generation occurs both inside the red blood cells and inside the vascular lumen, which augment hemolysis and cellular adhesion. This review discusses the evolving body of literature on the role of ROS in the pathophysiology of SCD as well as some emerging therapeutic approaches to SCD with a focus on the reduction of ROS.

PMID:
29222291
PMCID:
PMC6142561
DOI:
10.1182/asheducation-2017.1.440
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center